RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that Ken Song, M.D., President and CEO of the Company, will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023.
J.P. Morgan Healthcare Conference
Date: Monday, January 9, 2023
Time: 2:00 p.m. - 2:25 p.m. PST
Location: The Westin St. Francis – Golden Gate Room
About RayzeBio
RayzeBio is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005346/en/
Contacts
Arvind Kush
info@rayzebio.com
